Answers are grounded in this paper and cite their sources.
Rising drug resistance underscores the urgent need for novel anti-influenza strategies. Targeting the hemagglutinin (HA)–sialic acid receptor interaction offers a promising broad-spectrum approach, yet progress is impeded by the lack of screening models that report the receptor-recognition step in a subtype-independent manner. Herein, we established a robust cell-based ELISA platform for high-throughput screening (HTS) that operates on the subtype-independent receptor-recognition step. The model utilizes ST6GAL1-overexpressing MDCK cells to enrich human-type α2,6-sialic acid receptors and employs horseradish peroxidase (HRP)-conjugated Sambucus nigra lectin (SNA) as a functional, though not structural, surrogate for the receptor-recognition step, yielding a high Z’ factor of 0.78. Given that SNA is a lectin rather than HA, the assay cannot by itself distinguish HA-specific blockade from membrane-mediated or virucidal effects. Orthogonal validation is therefore required for every hit. Screening a library of 2600 compounds identified two hits, Hypericin and protoporphyrin IX (PPIX), which effectively blocked SNA–receptor recognition with IC50 values of 18.39 ± 6.23 μM and 9.77 ± 3.05 μM, respectively. An orthogonal flow cytometry assay with FITC-conjugated SNA reproduced this inhibition on intact cells in a dose-dependent manner (IC50 = 17.68 ± 9.54 μM for Hypericin and 25.31 ± 19.47 μM for PPIX), confirming that the inhibition is not an artifact of the colorimetric readout. Hemagglutination inhibition (HA) assays with distinct pre-incubation strategies indicated that both compounds act on the viral particle rather than on the host receptor. Surface plasmon resonance (SPR) and molecular docking studies further indicated direct, dose-dependent but low-affinity binding to HA proteins. Notably, cytopathic effect (CPE) assays demonstrated their potent antiviral efficacy across H1N1 and H3N2 subtypes, with PPIX exhibiting exceptionally potent activity against H3N2 (EC50 = 0.50 ± 0.17 μM). Taken together, these data identify Hypericin and PPIX as viral-side attachment inhibitors with weak HA binding and multimodal antiviral activity. Because neither a virucidal nor a fusion-blocking control was included, the relative contribution of HA engagement to their overall antiviral effect remains to be established. In conclusion, this BSL-1-compatible ELISA platform, which probes the subtype-independent receptor-recognition step, provides an efficient tool for discovering broad-spectrum influenza entry inhibitors, and the identified hits offer novel pharmacological scaffolds for further structural optimization.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: